KR20190114910A - 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 - Google Patents
상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 Download PDFInfo
- Publication number
- KR20190114910A KR20190114910A KR1020190037310A KR20190037310A KR20190114910A KR 20190114910 A KR20190114910 A KR 20190114910A KR 1020190037310 A KR1020190037310 A KR 1020190037310A KR 20190037310 A KR20190037310 A KR 20190037310A KR 20190114910 A KR20190114910 A KR 20190114910A
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- phenyl
- group
- chloro
- methylmethanesulfonamide
- Prior art date
Links
- 0 C*([n]1c2ccccc2c(-c(nc(Nc(ccc(N(CC2)CCC2N2CCN(C)CC2)c2)c2OC)nc2)c2Cl)c1)=O Chemical compound C*([n]1c2ccccc2c(-c(nc(Nc(ccc(N(CC2)CCC2N2CCN(C)CC2)c2)c2OC)nc2)c2Cl)c1)=O 0.000 description 2
- HTTQVYCVJYZCLY-UHFFFAOYSA-N CN(CC1)CCN1C(CC1)CCN1c(cc1)cc(OC)c1Nc(nc1)nc(Nc2ccccc2N(CCC2)S2(=O)=O)c1Cl Chemical compound CN(CC1)CCN1C(CC1)CCN1c(cc1)cc(OC)c1Nc(nc1)nc(Nc2ccccc2N(CCC2)S2(=O)=O)c1Cl HTTQVYCVJYZCLY-UHFFFAOYSA-N 0.000 description 1
- JPWPBIGPQLJUAC-UHFFFAOYSA-N CN(Cc(cccc1)c1Nc(nc(Nc(ccc(N(CC1)CCC1N1CCN(C)CC1)c1)c1OC)nc1)c1Cl)S(C)(=O)=O Chemical compound CN(Cc(cccc1)c1Nc(nc(Nc(ccc(N(CC1)CCC1N1CCN(C)CC1)c1)c1OC)nc1)c1Cl)S(C)(=O)=O JPWPBIGPQLJUAC-UHFFFAOYSA-N 0.000 description 1
- RXULKUNPYDJSAC-UHFFFAOYSA-N CN(c(cccc1)c1Nc(nc(Nc(cc1F)ccc1N1CCC2(CCN(C)CC2)CC1)nc1)c1Br)S(C)(=O)=O Chemical compound CN(c(cccc1)c1Nc(nc(Nc(cc1F)ccc1N1CCC2(CCN(C)CC2)CC1)nc1)c1Br)S(C)(=O)=O RXULKUNPYDJSAC-UHFFFAOYSA-N 0.000 description 1
- FDTAOBCIVFVGHH-UHFFFAOYSA-N CN(c1ccccc1Nc(nc(Nc(ccc(N(CC1)CCC1N1CCN(C)CC1)c1)c1OC)nc1)c1Cl)S(C)(O)=O Chemical compound CN(c1ccccc1Nc(nc(Nc(ccc(N(CC1)CCC1N1CCN(C)CC1)c1)c1OC)nc1)c1Cl)S(C)(O)=O FDTAOBCIVFVGHH-UHFFFAOYSA-N 0.000 description 1
- GXSSXWSCTRZUIW-UHFFFAOYSA-N Cc(cc(cc1)Nc(nc2)nc(Nc(cccc3)c3N(C)S(C)(=O)=O)c2Cl)c1N1CCC2(CCN(C)CC2)CC1 Chemical compound Cc(cc(cc1)Nc(nc2)nc(Nc(cccc3)c3N(C)S(C)(=O)=O)c2Cl)c1N1CCC2(CCN(C)CC2)CC1 GXSSXWSCTRZUIW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180037654 | 2018-03-30 | ||
| KR1020180037654 | 2018-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190114910A true KR20190114910A (ko) | 2019-10-10 |
Family
ID=68060324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190037310A KR20190114910A (ko) | 2018-03-30 | 2019-03-29 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20190114910A (fr) |
| WO (1) | WO2019190259A1 (fr) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021125758A1 (fr) * | 2019-12-16 | 2021-06-24 | 주식회사 온코빅스 | Nouveau dérivé de pyrimidine substitué par du deutérium et composition pharmaceutique le comprenant |
| WO2022208454A1 (fr) * | 2021-04-02 | 2022-10-06 | Bridge Biotherapeutics, Inc. | Composés de n2-phénylpyrimidine-2,4-diamine et procédés de préparation et procédés d'utilisation correspondants |
| WO2022211573A1 (fr) | 2021-04-01 | 2022-10-06 | 주식회사 테라펙스 | Dérivé de pyrimidine ayant une activité inhibitrice de protéine kinase, et composition pharmaceutique thérapeutique le comprenant |
| KR20220136931A (ko) | 2021-04-01 | 2022-10-11 | 주식회사 테라펙스 | 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| WO2023287130A1 (fr) * | 2021-07-13 | 2023-01-19 | 한국화학연구원 | Nouveaux dérivés de pyrimidine-2,4-diamine, leur procédé de préparation et composition pharmaceutique les contenant en tant que principe actif pour la prévention ou le traitement du cancer |
| KR20230011244A (ko) * | 2021-07-13 | 2023-01-20 | 한국화학연구원 | 신규한 피리미딘-2,4-디아민 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| KR102524856B1 (ko) * | 2022-06-23 | 2023-04-24 | 주식회사 카나프테라퓨틱스 | 표피 성장인자 수용체 티로신 키나제에 대한 억제 활성을 갖는 신규 화합물 및 이의 용도 |
| WO2023106881A1 (fr) * | 2021-12-09 | 2023-06-15 | 주식회사 온코빅스 | Nouveau dérivé de pyrimidine à substitution hétérocyclique présentant un effet inhibiteur de la croissance des cellules cancéreuses, et composition pharmaceutique le contenant |
| WO2023163527A1 (fr) * | 2022-02-23 | 2023-08-31 | 주식회사 카나프테라퓨틱스 | Nouveau composé ayant une activité inhibitrice contre la tyrosine kinase du récepteur du facteur de croissance épidermique, et ses utilisations |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113166110B (zh) * | 2018-12-12 | 2023-08-11 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| KR102168179B1 (ko) * | 2019-10-31 | 2020-10-20 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
| CA3171776A1 (fr) * | 2020-04-14 | 2021-10-21 | Shansong ZHENG | Composes tricycliques servant d'inhibiteurs d'egfr |
| CN113717156B (zh) * | 2020-05-25 | 2023-05-09 | 南京红云生物科技有限公司 | Egfr抑制剂、其制备方法及用途 |
| CN113896744B (zh) * | 2020-07-06 | 2024-04-16 | 成都先导药物开发股份有限公司 | 一种选择性egfr抑制剂 |
| CN116490184A (zh) | 2020-09-11 | 2023-07-25 | J2H生物科技有限公司 | 用于抑制egfr突变癌症的化合物及其药物用途 |
| AU2021348463A1 (en) * | 2020-09-22 | 2022-03-31 | Beigene, Ltd. | Indoline compounds and derivatives as egfr inhibitors |
| CN116745280A (zh) * | 2020-09-30 | 2023-09-12 | 百济神州有限公司 | 用于降解egfr的双功能化合物和相关使用方法 |
| KR102685187B1 (ko) | 2021-10-15 | 2024-07-16 | 제이투에이치바이오텍 (주) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2717529A1 (fr) * | 2008-03-11 | 2009-09-17 | Cellzome Limited | Sulfonamides en tant qu'inhibiteurs de zap-70 |
| KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| US8410126B2 (en) * | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
| AU2016276963C1 (en) * | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
-
2019
- 2019-03-29 WO PCT/KR2019/003697 patent/WO2019190259A1/fr active Application Filing
- 2019-03-29 KR KR1020190037310A patent/KR20190114910A/ko unknown
Non-Patent Citations (1)
| Title |
|---|
| Clin Cancer Res. 19(8), 2240, 2013 |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021125758A1 (fr) * | 2019-12-16 | 2021-06-24 | 주식회사 온코빅스 | Nouveau dérivé de pyrimidine substitué par du deutérium et composition pharmaceutique le comprenant |
| JP2023507943A (ja) * | 2019-12-16 | 2023-02-28 | オンコビクス・カンパニー・リミテッド | 新規な重水素置換ピリミジン誘導体及びこれを含む薬剤学的組成物 |
| AU2020406819B2 (en) * | 2019-12-16 | 2023-11-09 | Oncobix Co., Ltd. | Novel deuterium-substituted pyrimidine derivative and pharmaceutical composition comprising same |
| WO2022211573A1 (fr) | 2021-04-01 | 2022-10-06 | 주식회사 테라펙스 | Dérivé de pyrimidine ayant une activité inhibitrice de protéine kinase, et composition pharmaceutique thérapeutique le comprenant |
| KR20220136931A (ko) | 2021-04-01 | 2022-10-11 | 주식회사 테라펙스 | 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| WO2022208454A1 (fr) * | 2021-04-02 | 2022-10-06 | Bridge Biotherapeutics, Inc. | Composés de n2-phénylpyrimidine-2,4-diamine et procédés de préparation et procédés d'utilisation correspondants |
| WO2023287130A1 (fr) * | 2021-07-13 | 2023-01-19 | 한국화학연구원 | Nouveaux dérivés de pyrimidine-2,4-diamine, leur procédé de préparation et composition pharmaceutique les contenant en tant que principe actif pour la prévention ou le traitement du cancer |
| KR20230011244A (ko) * | 2021-07-13 | 2023-01-20 | 한국화학연구원 | 신규한 피리미딘-2,4-디아민 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2023106881A1 (fr) * | 2021-12-09 | 2023-06-15 | 주식회사 온코빅스 | Nouveau dérivé de pyrimidine à substitution hétérocyclique présentant un effet inhibiteur de la croissance des cellules cancéreuses, et composition pharmaceutique le contenant |
| WO2023163527A1 (fr) * | 2022-02-23 | 2023-08-31 | 주식회사 카나프테라퓨틱스 | Nouveau composé ayant une activité inhibitrice contre la tyrosine kinase du récepteur du facteur de croissance épidermique, et ses utilisations |
| KR102524856B1 (ko) * | 2022-06-23 | 2023-04-24 | 주식회사 카나프테라퓨틱스 | 표피 성장인자 수용체 티로신 키나제에 대한 억제 활성을 갖는 신규 화합물 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019190259A1 (fr) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190114910A (ko) | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 | |
| US11731984B2 (en) | KRas G12C inhibitors | |
| US9884861B2 (en) | Compositions useful for treating disorders related to kit | |
| AU2013300344B2 (en) | N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer | |
| US9890168B2 (en) | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| US10899764B2 (en) | Imidazo isoindole derivative, preparation method therefor and medical use thereof | |
| TWI669300B (zh) | 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途 | |
| RU2692479C2 (ru) | (5,6-дигидро)пиримидо[4,5-е]индолизины | |
| JP5993010B2 (ja) | ピリミド−ピリダジノン化合物及びその使用 | |
| US11608334B2 (en) | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | |
| JP6057907B2 (ja) | チアゾリジン誘導体又はその塩を有効成分とする医薬品 | |
| KR20130046436A (ko) | 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도 | |
| CN106488918B (zh) | 三唑并嘧啶酮或三唑并吡啶酮衍生物及其用途 | |
| EP2501233B1 (fr) | Composés de quinazoline | |
| PT1465921E (pt) | Espirocíclico-6, 7-di-idro-5h-pirazolo[1,2-a] pirazol-1-onas que controlam citocinas inflamatórias | |
| JP7449028B2 (ja) | Ｅｇｆｒ阻害剤およびその製造方法と応用 | |
| US20230303575A1 (en) | Fgfr and mutation inhibitor thereof, preparation method therefor and use thereof | |
| EA029269B1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| KR20210039228A (ko) | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 피리미디나다이벤젠아사이클로헵타판 유도체 | |
| CN115611888A (zh) | 吡啶并嘧啶酮类衍生物及其制备方法和用途 | |
| CN102190669A (zh) | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 | |
| RU2811207C1 (ru) | Fgfr и его ингибитор мутаций, способ его получения и его применение | |
| RU2804709C2 (ru) | Соединения для лечения некоторых лейкозов | |
| KR20230104163A (ko) | 암 치료용 벤조[h]퀴나졸린-4-아민 및 티에노[3,2-h]퀴나졸린-4-아민 유도체 | |
| WO2022258057A1 (fr) | Composés en tant qu'agents anticancéreux |